NMN cost in 2026: price per gram, best value, and the regulatory cloud to know about

“How much does NMN cost?” looks like a simple question and isn’t, because the number on the bottle hides three things that decide what you actually pay: the dose you take, the purity you get, and a regulatory wrinkle unique to this molecule. NMN is an oral supplement, so unlike an IV drip or a compounded injection there’s no clinic time baked into the price — the whole cost is the powder in the capsule. That makes NMN a pure price-per-effective-dose problem, with one twist the supplement aisle never mentions: in the United States, whether NMN is even allowed to be sold as a supplement is an open question. Here’s what a month of NMN runs in mid-2026, how to compare brands honestly, the regulatory cloud you should know about before you subscribe, and how to match the spend to what the science actually supports.

What a month of NMN actually costs

Strip away the marketing and NMN is a white powder sold by the gram. As of mid-2026, a bottle of a mainstream capsule or pure-powder NMN at a common daily dose — roughly 250 to 500 mg a day — lands in the neighborhood of $30 to $70 a month, with subscription tiers and bulk-powder formats pulling the low end down and premium, single-batch-tested capsules pushing the high end up. That band is wide for a reason: two bottles at the same sticker price can deliver very different amounts of NMN. One might be 60 capsules at 250 mg (a month at one-a-day, two weeks at the more common two-a-day); another might be 30 capsules at 500 mg. The shelf price tells you almost nothing until you convert it.

Why purity and testing belong in the price

Cost per gram only means something if the gram is real. NMN is an unstable molecule and an attractive one to cut, so a bargain powder can list 500 mg per serving and assay lower, or carry impurities that the label never mentions. The defensible premium in this category is paid for third-party testing — a certificate of analysis confirming identity, the stated dose, and the absence of contaminants. A brand that publishes batch testing and one that doesn’t are not selling the same product at different prices; they’re selling different products. When you compute cost per gram, compute it on the verified gram, and treat an untested cut-rate powder the way you’d treat any unverified supplement: the low number is only a bargain if the contents match the claim.

The regulatory cloud over NMN

Here is the twist that makes NMN’s cost story different from any other longevity capsule. In late 2022 the U.S. Food and Drug Administration took the position that NMN is excluded from the legal definition of a dietary supplement — the agency’s reasoning being that NMN had been authorized for investigation as a new drug before it was marketed as a supplement, which under the statute can knock an ingredient out of supplement status.^[3] The agency has not pulled NMN from shelves, and it remains widely and openly sold, but the underlying legal question is unresolved — a cloud, not a ban.

For a buyer, this matters in two practical ways. First, supply and pricing can be less stablethan for a settled ingredient: an unresolved status means a given brand or marketplace could restrict, relabel, or reprice NMN with little warning, so a great per-gram deal today isn’t a guarantee of the same deal on your next refill. Second, it reframes the NMN-versus-NR decision below — one of those precursors sits inside the regulatory cloud and one largely doesn’t. None of this is a claim that NMN is unsafe; it’s a claim that the rules around it are unsettled, and an informed shopper should price that uncertainty in rather than discover it at checkout.

NMN vs. NR: the value question behind the price

The two leading oral NAD+ precursors are NMN and nicotinamide riboside (NR), and the choice between them is partly a value calculation. NR — sold most prominently as the patented ingredient Niagen — was commercialized through the supplement framework and largely sits outside the specific drug-exclusion question hanging over NMN, which is a meaningful tick in its column even when its per-gram price is similar or a little higher. On the evidence side the two are close cousins: both reliably raise blood NAD+ in randomized human trials, and neither has shown that doing so extends human healthspan. We compare the underlying trial data head-to-head in our NAD+ precursors (NR and NMN) evidence review, and the NAD+ format comparator lays the routes side by side on cost and convenience. The short version: NMN often wins on raw per-gram price and NR often wins on regulatory cleanliness, so the “best value” pick depends on which of those you weight more heavily.

Cost versus evidence: what your money is really buying

The organizing principle for NMN spending is the same one that governs the whole NAD+ category: you are buying a biomarker, not an outcome. The headline NMN trial that everyone cites enrolled postmenopausal women with prediabetes and found a gain in muscle insulin sensitivity among those taking the compound — a real, peer-reviewed randomized result, but a small one, in a narrow population, on a surrogate measure rather than a hard clinical outcome.^[1] A larger, dose-ranging randomized, double-blind, placebo-controlled trial in healthy middle-aged adults found NMN was well-tolerated and moved physiological measures in a dose-dependent way — again, useful and reassuring on safety, and again on modest, surrogate endpoints rather than proof of a longer or healthier life.^[2] That evidence tier is exactly what should set your budget: NMN is supplement-priced for supplement-grade evidence, and paying premium-longevity prices for it assumes a benefit the trials have not shown. To see how NMN stacks up against other interventions on that score, our longevity evidence matrix grades it so you’re not paying outcome prices for biomarker data.

How NMN fits the wider NAD+ cost picture

Oral NMN is the cheapest seat in the NAD+ category by a wide margin. The same molecule’s coenzyme can be sold as a subcutaneous NAD+ injection or an IV drip, where the price climbs into the hundreds of dollars a month or per session — and, paradoxically, the controlled-outcome evidence gets thinner as the bill gets bigger. The only human study of an intravenous infusion of the coenzyme tracked how quickly it left the plasma, not any clinical benefit; we walk through that in NAD+ IV therapy and the evidence it’s priced ahead of. So an oral NMN capsule isn’t just the budget option — for the core claim of raising blood NAD+, it’s the route with the strongest human data attached to the lowest price. If you do want a clinician-supervised program, our curated NAD+ therapy provider rankings sort the legitimate options so you can pair what you pay with the care model on offer.

The honest bottom line

A month of oral NMN realistically costs about $30 to $70 at common doses, but the only number that lets you compare brands is cost per gram of verified NMN — run that calculation and most of the price confusion disappears. Two things should temper the bargain-hunting: the unresolved U.S. regulatory status of NMN, which makes a given cheap source less of a sure thing than it looks, and the evidence tier, which is genuine but surrogate-marker-level. NR is the close substitute that trades a similar price for a cleaner regulatory footing. Pay NMN like the supplement it is — priced per effective gram, bought from a brand that proves what’s in the bottle, and anchored to evidence that shows a moved biomarker, not a longer life.